Spots Global Cancer Trial Database for Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Official Title: PNT2258-02: A Pilot Phase II Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Study ID: NCT01733238
Conditions
Interventions
Study Description
Brief Summary: This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It study is a multi-center, nonrandomized, open-label, pilot Phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory lymphoma.
Detailed Description: PNT2258 will be administered at a dose of 120 mg/m2, as a 3-hour intravenous (IV) infusion on days 1-5 of a 21-day cycle. Treatment may continue (unless there is disease progression or the occurrence of unacceptable toxicity) for a total of 6 cycles of therapy.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Horizon Oncology Research, Inc., Lafayette, Indiana, United States
Cancer and Hematology Centers of Western Michigan, P.C., Grand Rapids, Michigan, United States
St. John Hospital and Medical Center, Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States
Contact Details
Name: Barbara Klencke, M.D.
Affiliation: Sierra Oncology LLC - a GSK company
Role: STUDY_CHAIR
Name: Ayad Al-Katib, MD
Affiliation: St. John Hospital and Medical Center, Van Elslander Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
